has occurred with anti– PD-1/PD-L1 treatments. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes. Withhold or permanently discontinue ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

"These approvals underscore the continued expansion of the use of KEYTRUDA in diverse patient populations and treatment settings with utility of KEYTRUDA ranging from earlier lines of therapy to ...

If you have pneumonitis with Keytruda, your doctor might prescribe corticosteroid treatment for you. Additionally, your doctor may recommend that you temporarily or permanently stop taking Keytruda.

"These approvals underscore the continued expansion of the use of KEYTRUDA in diverse patient populations and treatment settings with utility of KEYTRUDA ranging from earlier lines of therapy to ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

If you are facing a recurrence of classic Hodgkin lymphoma, or you have become resistant to your treatment, there is some ...

There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...